The latest price target for BioAtla (NASDAQ:BCAB) was reported by HC Wainwright & Co. on November 13, 2024. The analyst firm set a price target for $0.00 expecting BCAB to fall to within 12 months (a possible -100.00% downside). 7 analyst firms have reported ratings in the last year.

The latest analyst rating for BioAtla (NASDAQ:BCAB) was provided by HC Wainwright & Co., and BioAtla downgraded their neutral rating.

There is no last upgrade for BioAtla

The last downgrade for BioAtla Inc happened on November 13, 2024 when HC Wainwright & Co. changed their price target from N/A to N/A for BioAtla Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BioAtla, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BioAtla was filed on November 13, 2024 so you should expect the next rating to be made available sometime around November 13, 2025.

While ratings are subjective and will change, the latest BioAtla (BCAB) rating was a downgraded with a price target of $0.00 to $0.00. The current price BioAtla (BCAB) is trading at is $1.39, which is out of the analyst’s predicted range.